精品久久久久99999,久草视频在线最免费

項目背景：

公司專注于傳染性疾病領(lǐng)域的創(chuàng)新藥物研發(fā)及商業(yè)化，致力于為中國和全球患者提供可負擔(dān)的高品質(zhì)新型治療方案。
The company focuses itself in the development and commercialization of innovative drugs for infectious diseases, and is committed to providing affordable and high-quality new treatment solutions for patients in China and around the world.

公司生物醫(yī)藥采取“3I”戰(zhàn)略(創(chuàng)新Innovation、整合Integration和國際化Internationalization)，聯(lián)合中科院武漢病毒所和中科院上海藥物研究所新藥研發(fā)優(yōu)勢，充分利用九州通已建立的商業(yè)化渠道優(yōu)勢，使越來越多的創(chuàng)新藥惠及大眾，推動我國藥品創(chuàng)新與服務(wù)的高質(zhì)量發(fā)展。
adopts the "3I" strategy (Innovation, Integration and Internationalization). By combining the strength of Wuhan Institute of Virology and Shanghai Institute of Materia Medica (Chinese Academy of Sciences) in new drug R&D, and by making full use of the well-established commercial channels from JoinTown Pharmaceutical Group, JKT BioPharma will be able to ensure accessibility of the public to more and more innovative drugs, and to bring drug innovation and services in China to a higher level.